Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Brotchie

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Parkinsonism & Related Disorders|August 21, 2012
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept studyTom H Johnston, Philippe Huot, Sammie Damude, et al.
Neuropharmacology|June 17, 2018
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's diseaseTom H Johnston, Alix M B Lacoste, Naomi P Visanji, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2019
Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's DiseasePatrick A Howson, Tom H Johnston, Paula Ravenscroft, et al.
EJNMMI Research|July 30, 2022
Toward in vivo proof of binding of <sup>18</sup>F-labeled inhibitor [<sup>18</sup>F]TRACK to peripheral tropomyosin receptor kinasesMelinda Wuest, Justin J Bailey, Jennifer Dufour, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 23, 2006
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptorsMichael P Hill, Paula Ravenscroft, Steven G McGuire, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2006
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Jordi Gomez-Ramirez, Tom H Johnston, et al.
The European Journal of Neuroscience|January 4, 2013
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaquePhilippe Huot, Tom H Johnston, Tessa Snoeren, et al.
Cells|April 5, 2020
The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's DiseaseSimoneide S Titze-de-Almeida, Cristina Soto-Sánchez, Eduardo Fernandez, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 26, 2003
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmosetMichael P Hill, Erwan Bezard, Steven G McGuire, et al.
Trends in Neurosciences|November 8, 2016
α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New EraNaomi P Visanji, Jonathan M Brotchie, Lorraine V Kalia, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Parkinsonism & Related Disorders|August 21, 2012
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept studyTom H Johnston, Philippe Huot, Sammie Damude, et al.
Neuropharmacology|June 17, 2018
Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's diseaseTom H Johnston, Alix M B Lacoste, Naomi P Visanji, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2019
Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's DiseasePatrick A Howson, Tom H Johnston, Paula Ravenscroft, et al.
EJNMMI Research|July 30, 2022
Toward in vivo proof of binding of <sup>18</sup>F-labeled inhibitor [<sup>18</sup>F]TRACK to peripheral tropomyosin receptor kinasesMelinda Wuest, Justin J Bailey, Jennifer Dufour, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 23, 2006
Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptorsMichael P Hill, Paula Ravenscroft, Steven G McGuire, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 9, 2006
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's diseaseNaomi P Visanji, Jordi Gomez-Ramirez, Tom H Johnston, et al.
The European Journal of Neuroscience|January 4, 2013
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaquePhilippe Huot, Tom H Johnston, Tessa Snoeren, et al.
Cells|April 5, 2020
The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's DiseaseSimoneide S Titze-de-Almeida, Cristina Soto-Sánchez, Eduardo Fernandez, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 26, 2003
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmosetMichael P Hill, Erwan Bezard, Steven G McGuire, et al.
Trends in Neurosciences|November 8, 2016
α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New EraNaomi P Visanji, Jonathan M Brotchie, Lorraine V Kalia, et al.
Pageof 13